Previously, combinations of sub-optimal doses of the DACRA KBP-089 and the GLP-1 agonist liraglutide were shown to act complementarily on body weight, food intake and glucose tolerance [13, 14], indicating the add-on potential of KBP-089 to liraglutide in obesity treatment. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.